EVMN · Evommune, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · EVMN
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Revenue | $3.00M | - | $10.00M |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| R&D | $14.36M | - | $19.64M |
| SG&A | $3.67M | - | $3.69M |
| Total Operating Expenses | $18.03M | - | $16.52M |
| D&A | $200.0K | - | - |
| Operating Income | ($15.03M) | - | ($13.33M) |
| Interest Expense | - | - | - |
| Income Tax | $0 | - | $0 |
| Net Income | ($14.56M) | - | ($15.92M) |
| EPS - Basic | ($0.64) | - | ($8.07) |
| EPS - Diluted | ($9.48) | - | ($10.47) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Cash & Equivalents | $5.70M | $44.06M | $18.15M |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Accounts Payable | $4.04M | $7.76M | $8.26M |
| Current Assets | $215.85M | $153.48M | $81.94M |
| Total Assets | $322.45M | $224.95M | $84.54M |
| Current Liabilities | $10.60M | $17.91M | $10.42M |
| Long-term Debt | - | - | - |
| Total Liabilities | $17.90M | $19.38M | $28.52M |
| Stockholders' Equity | $304.56M | $205.57M | ($107.03M) |
| Retained Earnings | ($242.76M) | ($221.09M) | ($192.82M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Operating Cash Flow | ($23.90M) | - | - |
| Investing Cash Flow | $13.50M | - | - |
| Financing Cash Flow | ($152.0K) | - | - |
| CapEx | $83.0K | - | - |
| Free Cash Flow | ($23.98M) | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | -501.1% | - | -133.3% |
| EBITDA margin | -494.4% | - | - |
| Net margin | -485.2% | - | -159.2% |
| Free cash flow margin | -799.4% | - | - |
| FCF / Net income | 1.65 | - | - |
| R&D / Revenue | 478.7% | - | 196.4% |
| SG&A / Revenue | 122.3% | - | 36.9% |
| Effective tax rate | - | - | - |
| Return on assets | -4.5% | - | -18.8% |
| Return on equity | -4.8% | - | 14.9% |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 20.36 | 8.57 | 7.87 |
| Quick ratio | 20.36 | 8.57 | 7.87 |
| Cash ratio | 0.54 | 2.46 | 1.74 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | 1.06 | 1.09 | -0.79 |
| Liabilities / Assets | 0.06 | 0.09 | 0.34 |
| Efficiency | |||
| Asset turnover | 0.01 | - | 0.12 |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | - |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | 0.1x | - | - |
| P / S | 11.8x | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | - | - | - |
| Net income growth (YoY) | - | - | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | - | - | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Evommune against the 5 most active filers in the same SIC group.